QIAGEN to join Germany’s MDAX index in addition to TecDAX
QIAGEN to join MDAX as of September 24, 2018, due to reorganization of German stock market indices
Hilden, Germany, and Germantown, Maryland, September 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its global shares will be included in Germany’s MDAX index as of September 24, 2018, in addition to the current listing in the country’s TecDAX index.
The addition to the MDAX – which will now track the next 60 largest companies on the German stock market after the 30 largest stocks in the DAX index – comes as part of a reorganization of index rules adopted by Deutsche Boerse, operator of the Frankfurt Stock Exchange.
The new rules for the indices remove the previous separation of companies into the “Tech” segment (in which QIAGEN has been a member since 2003) and the “Classic” segment (traditional businesses). Technology sector companies will now be eligible for listing in the DAX, MDAX or SDAX based on market capitalization and trading volume, while also being eligible for membership in the TecDAX, which will continue to comprise the 30 largest technology companies measured by market capitalization and sales.
“The MDAX and TecDAX indices are each used as performance benchmarks by some investors, especially through the use of exchange-traded funds (ETFs), and we believe the changes in the German stock market indices will create additional opportunities for QIAGEN’s global shares to be held by investors around the world,” said Roland Sackers, Chief Financial Officer of QIAGEN N.V.
The changes in the German stock market indices have no impact on the listing of QIAGEN’s global shares on the New York Stock Exchange.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2018, QIAGEN employed approximately 4,800 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).